Schrodinger Inc. Common Stock (SDGR)
Stock · NASDAQ · Health Care
$22.61as of 10/16/2026
Price chart
Active signals
SDGR Signal Track Record
How signals performed across all stocks →What SDGR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -1.4% | 43% | October 1, 2026 |
| Bollinger Band Breakout | 25 | -4.9% | 44% | September 15, 2026 |
| Bollinger Band BreakdownActive now | 20 | +0.2% | 55% | March 25, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -4.5% | 33% | July 30, 2026 |
| Any 20-session window (baseline) | -0.4% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SDGR
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 850
- Website
- www.schrodinger.com
Fundamentals
- 1-day range
- $22.57$26
- Market cap
- $1.33B
- P/E (trailing)
- —
- P/E (forward)
- -16.74
- EPS (trailing)
- $-0.74
- Dividend yield
- —
- Beta
- 1.62
- Avg. volume
- 1.85M
How Schrodinger Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Schrodinger Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
- MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$9.55▼ 6.92%Market cap $1.33BP/E —$8.8$23.29
- ORICOric Pharmaceuticals Inc. Common Stock$12.35▼ 3.29%Market cap $1.34BP/E —$7.23$14.68
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | $1.33B | — | $9.55 | ▼ 6.92% | $8.8$23.29 |
| ORIC Oric Pharmaceuticals Inc. Common Stock | $1.34B | — | $12.35 | ▼ 3.29% | $7.23$14.68 |
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Keybanc Maintains Overweight on Schrodinger, Raises Price Target to $32benzinga · 10/16/2026
- What Could Go Wrong With Recursion Pharmaceuticals Stock?Yahoo · 10/8/2026
- Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?Yahoo · 10/6/2026
- 'HHS launches project to speed up clinical trials' - AxiosBenzinga · 9/30/2026
- Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise YouBenzinga · 9/29/2026
- Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha · 9/29/2026
- Schrödinger (SDGR) Could Be 29% Below Fair Value Despite A 38% Overvalued ViewYahoo · 9/27/2026
- Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?Yahoo · 9/24/2026
- Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene EditingSeekingAlpha · 9/24/2026
Insider Activity
Insider Actions →- Akinsanya Karen · September 17, 2026 · Option Exercise31.6K @ $4.34
- Akinsanya Karen · September 17, 2026 · Sale21.6K @ $30
- Akinsanya Karen · September 17, 2026 · Sale10.0K @ $28
- Jain Rachit · July 16, 2026 · Sale875 @ $15.6
- Friesner Richard · June 22, 2026 · Grant13.3K
- Friesner Richard · June 22, 2026 · Grant8.1K
- Kapeller-Libermann Rosana · June 22, 2026 · Grant13.3K
- Kapeller-Libermann Rosana · June 22, 2026 · Grant8.1K
- Nancy Thornberry · June 22, 2026 · Grant13.3K
- Nancy Thornberry · June 22, 2026 · Grant8.1K
- Gary Sender · June 22, 2026 · Grant13.3K
- Gary Sender · June 22, 2026 · Grant8.1K
- Jeffrey Chodakewitz · June 22, 2026 · Grant13.3K
- Jeffrey Chodakewitz · June 22, 2026 · Grant8.1K
- Michael Lynton · June 22, 2026 · Grant13.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 62.05M
- Total value held
- $687.74M
- Institutional holders
- 222
- Unknown9.68M
- Unknown6.98M
- Unknown6.00M
- Unknown3.19M
- Unknown3.19M
- Unknown2.68M
- Unknown2.66M
- Unknown2.60M
- Unknown2.19M
- Unknown2.07M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Schrödinger (SDGR) Announces New Battery Research, Analyst Targets Rise
Schrödinger’s research team published a study in Nature that provides new insights into lithium‑ion battery chemistry, showcasing the company’s computational chemistry capabilities. Analyst houses TD Cowen and BMO Capital each lifted their price targets, citing the potential impact of the battery work and broader AI applications. At the same time, other analysts expressed mixed views on the company’s AI growth, resulting in a modest upward adjustment to its fair‑value estimate.
Schrödinger (SDGR) Announces New Battery Research, Analyst Targets Rise. Schrödinger’s research team published a study in Nature that provides new insights into lithium‑ion battery chemistry, showcasing the company’s computational chemistry capabilities. Analyst houses TD Cowen and BMO Capital each lifted their price targets, citing the potential impact of the battery work and broader AI applications. At the same time, other analysts expressed mixed views on the company’s AI growth, resulting in a modest upward adjustment to its fair‑value estimate.